| CAS | 141676-35-9 |
| Sequence | H-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH (Disulfide bond) |
| Sequence Single | GLSKGCFGLKLDRIGSMSGLGCNSFRY |
| Molecular Formula | C124H198N36O36S3 |
| Molecular Weight | 2865.36 |
| Synonyms | Vasonatrin Peptide (1-27) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cardiovascular System & Diseases |
| Description | Vasonatrin Peptide (VNP) also called Vasonatrin Peptide (1-27), is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway. |
| References | 1. Synthesis of new oligopeptides and their scavenging abilities against active oxygen species. J.Ueda et al., Biochem. Mol. Biol. Int., 33, 1041 (1994) 2. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. Wei CM, et al. J Clin Invest. 1993;92(4):2048-2052. 3. Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes. Chen BY, et al. J Endocrinol Invest. 2011;34(10):742-746. 4. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Shi Z, et al. Am J Physiol Heart Circ Physiol. 2015;308(4):H281-H290. |